Protagonist Therapeutics Inc PTGX:NASDAQ

Last Price$7.92NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/20/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$7.20 (2)
Ask (Size)$8.00 (25)
Day Low / HighN/A - N/A
Volume1.2 M

Protagonist Therapeutics Announces 'Positive Data' for Rusfertide as Possible Hereditary Hemochromatosis Treatment

11:05AM ET 11/15/2021 MT Newswires
Protagonist Therapeutics (PTGX) said Monday that results from a study to evaluate rusfertide as an investigational drug to treat hereditary hemochromatosis.

The company said in a 24-week phase 2a study with 16 patients the drug showed "favorable safety, tolerability, and therapeutic effect."

Hereditary hemochromatosis is a genetic disorder that causes the body to absorb too much iron, Protagonist said.

Price: 37.24, Change: +0.14, Percent Change: +0.38